IRIS
MARTINI, Giulia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.334
NA - Nord America 2.636
AS - Asia 2.408
SA - Sud America 307
Continente sconosciuto - Info sul continente non disponibili 213
AF - Africa 35
OC - Oceania 4
Totale 10.937
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 3.816
US - Stati Uniti d'America 2.573
SG - Singapore 843
IE - Irlanda 475
CN - Cina 468
HK - Hong Kong 421
IT - Italia 410
VN - Vietnam 288
BR - Brasile 263
DE - Germania 188
KR - Corea 134
GB - Regno Unito 115
IN - India 80
FR - Francia 73
UA - Ucraina 54
JP - Giappone 44
CA - Canada 38
FI - Finlandia 35
SE - Svezia 31
AT - Austria 26
GR - Grecia 25
PK - Pakistan 25
TR - Turchia 22
NL - Olanda 21
BD - Bangladesh 20
PL - Polonia 17
AR - Argentina 15
MX - Messico 14
CZ - Repubblica Ceca 12
EC - Ecuador 12
ID - Indonesia 12
IQ - Iraq 12
ZA - Sudafrica 10
ES - Italia 9
BE - Belgio 8
CO - Colombia 7
MA - Marocco 7
CH - Svizzera 6
AZ - Azerbaigian 5
UZ - Uzbekistan 5
AU - Australia 4
DO - Repubblica Dominicana 4
DZ - Algeria 4
KE - Kenya 4
KG - Kirghizistan 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
PH - Filippine 3
TT - Trinidad e Tobago 3
VE - Venezuela 3
AL - Albania 2
CL - Cile 2
CR - Costa Rica 2
GI - Gibilterra 2
JO - Giordania 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LT - Lituania 2
MY - Malesia 2
PE - Perù 2
PY - Paraguay 2
SN - Senegal 2
TH - Thailandia 2
TW - Taiwan 2
AM - Armenia 1
AO - Angola 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
EG - Egitto 1
GA - Gabon 1
HN - Honduras 1
HU - Ungheria 1
IL - Israele 1
IR - Iran 1
IS - Islanda 1
LB - Libano 1
PT - Portogallo 1
RO - Romania 1
SA - Arabia Saudita 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TJ - Tagikistan 1
Totale 10.724
Salva come PNG Salva come JPEG
Città #
Moscow 1.382
San Jose 494
Dublin 465
Singapore 421
Hong Kong 408
Santa Clara 328
Chandler 220
Ashburn 149
Seoul 133
Council Bluffs 103
Naples 98
Jacksonville 96
Ho Chi Minh City 94
Beijing 90
New York 80
Hefei 73
Hanoi 69
Dallas 68
Los Angeles 68
Munich 61
Bremen 55
Princeton 54
Roxbury 54
Bengaluru 43
The Dalles 40
Ann Arbor 30
Cambridge 30
Caserta 25
Medford 24
Da Nang 22
São Paulo 21
Rome 16
Vienna 16
Chicago 15
Haiphong 15
Aversa 14
Warsaw 14
Nuremberg 13
Atlanta 12
Brooklyn 12
Des Moines 12
Amsterdam 11
Boardman 11
Brno 11
Elora 11
Orem 11
Tokyo 11
Turku 11
Wilmington 11
Frankfurt am Main 10
Milan 10
Rio de Janeiro 10
San Francisco 10
Falkenstein 9
Napoli 9
Piscataway 9
Chennai 8
Helsinki 8
Hải Dương 8
Lappeenranta 8
Rawalpindi 8
Shanghai 8
Tianjin 8
Brussels 7
Hillsboro 7
Houston 7
Montreal 7
Bologna 6
City of London 6
Columbus 6
Denver 6
Dong Ket 6
Ercolano 6
Jakarta 6
Jinan 6
London 6
Memphis 6
Nanjing 6
San Mateo 6
Woodbridge 6
Bahawalpur 5
Baku 5
Battipaglia 5
Belo Horizonte 5
Buffalo 5
Campinas 5
Guangzhou 5
Guayaquil 5
Istanbul 5
Manchester 5
Mountain View 5
Mumbai 5
Ninh Bình 5
Anantapur 4
Baghdad 4
Bari 4
Bishkek 4
Biên Hòa 4
Boston 4
Changsha 4
Totale 5.847
Salva come PNG Salva come JPEG
Nome #
Beyond N staging in colorectal cancer: Current approaches and future perspectives 226
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 211
AXL is an oncotarget in human colorectal cancer 196
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 187
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 185
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 179
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 176
Immunotherapy for head and neck cancer: Present and future 175
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 164
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 164
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 164
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 163
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 162
Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial 162
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 161
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 160
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 155
Cancer cells adapt FAM134B/BiP mediated ER-phagy to survive hypoxic stress 154
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 153
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 152
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 152
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 151
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 150
Clinical management of metastatic colorectal cancer in the era of precision medicine 150
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 148
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 148
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 147
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial 147
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 147
Pimasertib hydrochloride 146
Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? 144
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 143
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial 141
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 140
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? 138
Case report of unusual synchronous anal and rectal squamous cell carcinoma: clinical and therapeutic lesson 137
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 136
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 133
Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial 132
BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer 132
Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study 128
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer 126
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 126
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 126
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 125
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 125
A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy 124
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? 122
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 122
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 122
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer 120
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 120
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 119
Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives 119
Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation 118
How I treat anal squamous cell carcinoma 118
Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives 117
Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941 117
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 116
Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial 115
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data 113
Feasibility of next-generation sequencing in clinical practice: Results of a pilot study in the Department of Precision Medicine at the University of Campania ' Luigi Vanvitelli' 112
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC 111
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines 109
Skin toxicity as predictor of survival in refractory patients with ras wild‐type metastatic colorectal cancer treated with cetuximab and avelumab (Cave) as rechallenge strategy 107
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case 104
Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy 104
“Aging and epigenetic implications in radiotherapy: The promise of BNCT” 104
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression 103
Implication of the Hedgehog pathway in hepatocellular carcinoma. 102
ROLE OF THE HEDGEHOG PATHWAY IN MEDIATING RESISTANCE TO ANTI-EGFR TYROSINE KINASE INHIBITORS IN NON SMALL CELL LUNG CANCER 101
Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. 100
Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer 96
Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer 96
The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer 91
Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer 90
Targeting the EGFR signalling pathway in metastatic colorectal cancer 89
Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update 89
RNF43- And NOTCH1-mutated chemotherapy and Anti-EGFR-refractory colorectal cancer: Should clonality guide target prioritization with investigational therapies? 86
Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments 82
Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer 79
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial 21
First-line immunotherapy combination in squamous cell anal carcinoma: hope in a neglected disease 17
BRAFV600E mutant metastatic colorectal cancer: Current advances in personalized treatment and future perspectives 16
Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM study 15
Off-label drug use in oncology: integrating molecular and genetic analysis in an academic center's real-world approach 14
Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial 13
Cardio-Oncology Challenges in Elderly Patients 13
Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial 13
Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy 11
Totale 10.937
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.374
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.374
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022391 0 12 7 7 78 9 33 7 20 48 48 122
2022/2023939 99 17 25 71 125 78 4 41 426 8 26 19
2023/2024473 49 22 13 19 135 74 17 16 8 9 36 75
2024/20251.603 42 39 30 63 215 219 174 186 208 175 135 117
2025/20266.780 297 316 307 258 566 3.532 383 390 312 194 133 92
2026/2027235 61 174 0 0 0 0 0 0 0 0 0 0
Totale 10.937